Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

The oncologist ·Vol. 12 ·No. 12 ·2007-12-00 ·Pages 1467-9; author reply 1469-71

Metro G, Sperduti I, Russillo M, Milella M, Cognetti F, Fabi A

Abstract

暂无摘要

MeSH Terms

Adult Aged Antibodies, Monoclonal/pharmacology,therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents/pharmacology,therapeutic use Brain Neoplasms/drug therapy,mortality,secondary Breast Neoplasms/drug therapy,mortality,pathology Disease-Free Survival Female Humans Middle Aged Receptor, ErbB-2/antagonists & inhibitors Retrospective Studies Survival Rate Trastuzumab

Chemicals

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Receptor, ErbB-2 Trastuzumab

Authors & Affiliations

6 authors, click to expand affiliations / ORCID

Metro Giulio

Sperduti Isabella

Russillo Michelangelo

Milella Michele

Cognetti Francesco

Fabi Alessandra

Article Info

Journal

The oncologist

Abbr.

Oncologist

ISSN

1083-7159

DOI

10.1634/theoncologist.12-12-1467

Published

2007-12-00

Pages

1467-9; author reply 1469-71

Language

English

Region

United States

NLM ID

9607837

Subset

Corrections

CommentOn

PMID: 17673608

External Links

PubMed source DOI: 10.1634/theoncologist.12-12-1467 View journal details

Analysis Services

Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

Contact

WeChat Official Account